Bollard Group’s Editas Medicine EDIT Stock Holding History

Bollard Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-680	Closed	-$13K	–	321
2022 Q1	$13K	Hold	680	–	–	﹤0.01%	398
2021 Q4	$18K	Hold	680	–	–	﹤0.01%	395
2021 Q3	$28K	Hold	680	–	–	﹤0.01%	377
2021 Q2	$39K	Hold	680	–	–	﹤0.01%	361
2021 Q1	$29K	Hold	680	–	–	﹤0.01%	378
2020 Q4	$48K	Hold	680	–	–	﹤0.01%	340
2020 Q3	$19K	Hold	680	–	–	﹤0.01%	388
2020 Q2	$20K	Buy	+680	New	+$17.8K	﹤0.01%	411

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bollard Group's EDIT Position: Q2 2022 in Review

Bollard Group sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 680 shares — an estimated $13K sold.

Bollard Group first reported a position in EDIT in Q2 2020 and held it in 8 quarters. The position peaked at $48K in Q4 2020. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

Bollard Group reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 680 Editas Medicine shares in Q2 2022, an estimated $13K.
Bollard Group first reported a position in Editas Medicine in Q2 2020 and held it in 8 quarters.
Bollard Group's Editas Medicine position peaked at $48K in Q4 2020.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.